Torren Management’s Cytokinetics CYTK Stock Holding History

Torren Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-159	Closed	-$10.1K	–	1116
2025 Q4	$10.1K	Buy	+159	New	+$9.89K	0.01%	762

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Torren Management's CYTK Position: Q1 2026 in Review

Torren Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 159 shares — an estimated $10.1K sold.

Torren Management first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $10.1K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Torren Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Torren Management sold 159 Cytokinetics shares in Q1 2026, an estimated $10.1K.
Torren Management first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
Torren Management's Cytokinetics position peaked at $10.1K in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.